A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36.

A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. Abstract Text:

Sunghee Cho,Hazel H Szeto,Eunhee Kim,Hyunjoo Kim,Aaron T Tolhurst,John T Pinto,

Oxidative stress is implicated in the pathogenesis of ischemia/reperfusion injury. Recently, we demonstrated that activation of CD36, a class B scavenger receptor, mediates free radical production and tissue injury in cerebral ischemia (1). Oxidized low density lipoproteins (oxLDL) are among the ligands that bind to CD36 and are elevated in acute cerebral infarction. SS31 is a cell-permeable antioxidant peptide that reduces intracellular free radicals and inhibits LDL oxidation/lipid peroxidation (2). The current study was designed to investigate whether treatment with SS31 normalizes ischemia-induced redox changes and attenuates CD36-mediated tissue injury. C57BL/6 mice were subjected to transient middle cerebral artery occlusion (MCAO). Redox status and infarct volume were measured in animals treated with either saline or SS31. Oxidative stress induced by ischemia/reperfusion profoundly depleted glutathione (GSH) concentrations in the ipsilateral cortex and striatum. Treating mice with SS31 immediately after reperfusion significantly attenuated ischemia-induced GSH depletion in the cortex and reduced infarct size. By contrast, the protective effect of SS31 was absent in CD36 knock-out mice, indicating that SS31 is acting through inhibition of CD36. Treating C57BL/6 mice with SS31 reduced CD36 expression in postischemic brain and mouse peritoneal macrophages (MPM). Further in vitro studies revealed that SS31 attenuated oxLDL-induced CD36 expression and foam cell formation in MPM. These in vivo and in vitro studies indicate that the down-regulation of CD36 by novel class antioxidant peptides may be a useful strategy to treat ischemic stroke victims.

A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. Publishing Authors By Initials

S Cho,HH Szeto,E Kim,H Kim,AT Tolhurst,JT Pinto,

For similar cardiovascular diseases: vascular diseases: reperfusion injury research abstracts see: cardiovascular diseases: vascular diseases: reperfusion injury research

PUBMED ID PMID:

MEDLINE DATE:

A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: The Journal of biological chemistry

VOLUME: 282

Page Numbers: 4634-42

Journal Abbreviation: J. Biol. Chem.

ISSN: 0021-9258

DAY: 18

MONTH: 12

YEAR: 2006

A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2985121

A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. Keywords Mesh Terms:

KEYWORDS: Reperfusion Injury

MESH TERMS: pathology

Chemical & Substance for Abstract: A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. Information

Substance Name: oxidized low density lipoprotein

Registry Number: 0

Grant and Affiliation Information for A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36.

AFFILIATION: Burke Medical Research Institute, White Plains, New York 10605, USA. suc2002@med.cornell.edu

Country: United States

AGENCY: United States NINDS

GRANT: R21 NS048295

ACRONYM: NS

MEDLINETA: J Biol Chem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36 Related Publications

• "Being transformed by illness": adolescents' diabetes experience.
• 'It's really a hard life': love, gender and HIV risk among male-to-female transgender persons.
• A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36.
• A papillary fibroelastoma of the tricuspid valve.
• Biologically based complementary and alternative medicine use among breast cancer survivors: relationship to dietary fat consumption and exercise.
• Cancer-related beliefs and health behavior change among breast cancer survivors and their first-degree relatives.
• Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.
• Drug eluting stents for ST-elevation myocardial infarction: risk and benefit.
• Evaluating measurement uncertainty in the microbiological assay of vancomycin from methodology validation data.
• Human papillomavirus in oral squamous cells carcinoma in a population of 75 Brazilian patients.
• Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy.
• Pasteurella meningo-encephalitis--a risk of household pets.
• Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women.
• Polymorphisms of GSTP1 and GSTT1, but not of CYP2A6, CYP2E1 or GSTM1, modify the risk for esophageal cancer in a western population.
• Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes.
• Synthesis of aza- and thia-spiroheterocycles and attempted synthesis of spiro sulfonium compounds related to salacinol.
• The founder of a key European association. Interview by Ingrid Torjesen.
• Validation of erythromycin microbiological assay using an alternative experimental design.
• [Alberto's victory over ALS (amyotrophic lateral sclerosis): defense mechanism vs coping strategies]
• [Feeding disorders in children with gastro-esophageal reflux disease]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [What is an efficient health technology in Spain?]